PolyPid Ltd. Discusses SSI Unmet Need & SHIELD II Trial Update
Ticker: PYPD · Form: 6-K · Filed: Jun 18, 2024 · CIK: 1611842
| Field | Detail |
|---|---|
| Company | Polypid Ltd. (PYPD) |
| Form Type | 6-K |
| Filed Date | Jun 18, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial-update, medical-devices, healthcare
TL;DR
PolyPid hosted a call on SSIs and gave an update on their Phase 3 SHIELD II trial. Bullish on RELIDUR.
AI Summary
PolyPid Ltd. hosted a Key Opinion Leader (KOL) call on June 18, 2024, to discuss the significant unmet medical need in preventing surgical site infections (SSIs). The company also provided an update on its ongoing SHIELD II Phase 3 trial for its product, RELIDUR.
Why It Matters
This filing highlights the company's focus on addressing a critical healthcare issue and provides progress on a key clinical trial, which could impact future treatment options for SSIs.
Risk Assessment
Risk Level: medium — Clinical trial updates and discussions of unmet medical needs are important but do not guarantee regulatory approval or commercial success.
Key Players & Entities
- PolyPid Ltd. (company) — Registrant
- RELIDUR (product) — Product being tested in SHIELD II trial
- SHIELD II (trial) — Phase 3 clinical trial
FAQ
What is the primary focus of the KOL call hosted by PolyPid Ltd.?
The KOL call focused on the significant unmet medical need in preventing surgical site infections (SSIs).
What update was provided regarding the SHIELD II trial?
PolyPid Ltd. provided an update on its ongoing SHIELD II Phase 3 trial.
What is the product being discussed in relation to the SHIELD II trial?
The product is RELIDUR, which is being evaluated in the SHIELD II Phase 3 trial.
When was the press release incorporated into this 6-K filing issued?
The press release was issued on June 18, 2024.
What type of report is this filing?
This filing is a Report of Foreign Private Issuer (Form 6-K).
Filing Stats: 314 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2024-06-18 08:09:49
Filing Documents
- ea0207991-6k_polypid.htm (6-K) — 12KB
- ea020799101ex99-1_polypid.htm (EX-99.1) — 21KB
- 0001213900-24-053533.txt ( ) — 34KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. POLYPID LTD. Date: June 18, 2024 By: /s/ Dikla Czaczkes Akselbrad Name: Dikla Czaczkes Akselbrad Title: Chief Executive Officer 3